{"id":"amdx-2011p","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Vomiting"}]},"_chembl":{"chemblId":"CHEMBL458876","moleculeType":"Small molecule","molecularWeight":"252.23"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting SGLT2, AMDX-2011P reduces glucose reabsorption in the kidneys, leading to decreased blood glucose levels. This mechanism is particularly beneficial for patients with type 2 diabetes. The exact molecular details of how AMDX-2011P interacts with the SGLT2 receptor are not well understood.","oneSentence":"AMDX-2011P is a small molecule that targets the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:21:47.381Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT06514001","phase":"PHASE2","title":"A Study of AMDX-2011P in Participants With Alzheimer's Disease","status":"RECRUITING","sponsor":"Amydis Inc.","startDate":"2025-03-07","conditions":"Alzheimer Disease","enrollment":25},{"nctId":"NCT05709314","phase":"PHASE2","title":"A Study of AMDX-2011P in Participants With CAA","status":"RECRUITING","sponsor":"Amydis Inc.","startDate":"2024-07-09","conditions":"Cerebral Amyloid Angiopathy","enrollment":25},{"nctId":"NCT05542576","phase":"PHASE1, PHASE2","title":"Study of AMDX-2011P as a Retinal Tracer in Subjects With Neurodegenerative Diseases Associated With Amyloidogenic Proteinopathy","status":"COMPLETED","sponsor":"Amydis Inc.","startDate":"2022-08-24","conditions":"Parkinson Disease, Amyotrophic Lateral Sclerosis","enrollment":13},{"nctId":"NCT06223048","phase":"PHASE2","title":"A Study of AMDX-2011P in Participants With Primary Open Angle Glaucoma","status":"RECRUITING","sponsor":"Amydis Inc.","startDate":"2023-12-07","conditions":"Primary Open Angle Glaucoma","enrollment":50}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"AMDX-2011P","genericName":"AMDX-2011P","companyName":"Amydis Inc.","companyId":"amydis-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AMDX-2011P is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}